Avanzando en Salud Ósea: La Comisión Europea Autoriza los Biosimilares de Denosumab de Biocon Biologics

Biocon Biologics Austria Belgium France Germany Italy Netherlands Spain Switzerland United Kingdom India

y LinkedIn: Biocon para noticias de la empresa. 

Todas las demás marcas, estén registradas o no, son propiedad de sus respectivos titulares.

[1] Anna Strzelecka, Grzegorz Kania, Pawan Kumar Singh, Kuldeep Kumar, Binay Kumar Thakur, Ashwani Marwah, Sudipta Basu, Nitin Madhukar Chaudhari, Sarika S Deodhar, Elena Wolff-Holz, Sandeep Nilkanth Athalye, Subramanian Loganathan. A Randomized, Double-blind, Multicenter, Parallel-arm Phase 3 Study to Compare the Efficacy, Pharmacodynamics, Safety, and Immunogenicity between Bmab-1000 and Prolia in Postmenopausal Women with Osteoporosis. Poster presented at ACR Congress 2024

R. Eastell, E. Orwoll, F. Cosman, A. Strzelecka, G. Kania, R. Plebanski, A. Mansukhbhai Ranpura, K. Kumar, B. Kumar Thakur, A. Marwah, S. Basu, N. Madhukar Chaudhari, S. S Deodhar, E. Wolff-Holz, S. Loganathan. Equivalence Trial of Proposed Denosumab Biosimilar Bmab-1000 And Reference Denosumab In Postmenopausal Osteoporosis: The Devote Study. Poster presented at WCO-IEF-ESCEO 2025

[2] https://www.nhsinform.scot/illnesses-and-conditions/muscle-bone-and-joints/conditions-that-can-affect-multiple-parts-of-the-body/osteoporosis/#:~:text=Osteoporosis%20is%20a%20condition%20where,bone%20to%20fracture%20or%20break.

[3] https://www.osteoporosis.foundation/facts-statistics/epidemiology-of-osteoporosis-and-fragility- fractures#:~:text=Across%20Europe%20in%202019%20(European,aged%20%2B50)%20%5B7%5D 

[4] https://theros.org.uk/information-and-support/osteoporosis/osteoporosis-in-men/ 

[5] https://ecis.jrc.ec.europa.eu/sites/default/files/2024-01/jrc_CancerEstimates2022_factsheet.pdf 

[6] https://orthoinfo.aaos.org/en/diseases--conditions/giant-cell-tumor-of-bone/ 

[7] https://www.bcrt.org.uk/information/information-by-type/giant-cell-tumor/ 

[8] https://www.sciencedirect.com/science/article/pii/S2405844024069214#:~:text=Epidemiology,reportedly%20higher%20in%20Asian%20populations

Logo - https://mma.prnewswire.com/media/2724007/5399163/Biocon_Biologics_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/avanzando-en-salud-osea-la-comision-europea-autoriza-los-biosimilares-de-denosumab-de-biocon-biologics-302497327.html